NewcelX Ltd. announced on July 15, 2026, that it has been granted a patent in Brazil for NCEL-101, a treatment for Type 1 diabetes. This patent grant expands the company's global intellectual property portfolio. NewcelX Ltd. is a biotechnology company focused on developing therapeutic treatments.
